๐๐ก๐š๐ซ๐ฆ๐š ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐œ๐š๐ฅ๐ฅ๐ฌ ๐Ÿ๐จ๐ซ ๐‘&๐ƒ ๐Ÿ๐ฎ๐ง๐ ๐จ๐ฏ๐ž๐ซ๐ก๐š๐ฎ๐ฅ ๐ญ๐จ ๐๐ซ๐ข๐ฏ๐ž ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง

๐๐ก๐š๐ซ๐ฆ๐š ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐œ๐š๐ฅ๐ฅ๐ฌ ๐Ÿ๐จ๐ซ ๐‘&๐ƒ ๐Ÿ๐ฎ๐ง๐ ๐จ๐ฏ๐ž๐ซ๐ก๐š๐ฎ๐ฅ ๐ญ๐จ ๐๐ซ๐ข๐ฏ๐ž ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง

The pharmaceutical industry, led by PPMA Chairman Tauqeer Ul Haq, has urged reforms to the Central Research Fund (CRF), proposing that the 1% mandatory contribution be redirected to in-house R&D. This move aims to boost innovation, ensure global regulatory compliance, and reduce bureaucratic inefficiencies.

๐๐ก๐š๐ซ๐ฆ๐š ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐œ๐š๐ฅ๐ฅ๐ฌ ๐Ÿ๐จ๐ซ ๐‘&๐ƒ ๐Ÿ๐ฎ๐ง๐ ๐จ๐ฏ๐ž๐ซ๐ก๐š๐ฎ๐ฅ ๐ญ๐จ ๐๐ซ๐ข๐ฏ๐ž ๐ข๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง Read More ยป